OTSUKA PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 586
- Registration Number
- NCT00876343
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT00841568
Long Term Administration Study of OPC-12759 Ophthalmic Suspension
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 154
- Registration Number
- NCT00818324
Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: CDP870 400mgDrug: CDP870 100mgDrug: CDP870 200mgDrug: Placebo of CDP870
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 316
- Registration Number
- NCT00791999
Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 230
- Registration Number
- NCT00791921
Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.
Phase 3
Completed
- Conditions
- Cerebral Infarction
- Interventions
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1095
- Registration Number
- NCT00766545
A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2014-04-25
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 230
- Registration Number
- NCT00666965
A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2014-03-13
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT00606229
A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 59
- Registration Number
- NCT00606320
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 258
- Registration Number
- NCT00606281
© Copyright 2025. All Rights Reserved by MedPath